Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

The innate lymphoid cell (ILC) family is composed of natural killer (NK) cells, ILC1, ILC2 and
ILC3, which participate in immune responses to virus, bacteria, parasites and transformed …

Interest in adoptive cell therapy for treating cancer is exploding owing to early clinical
successes of autologous chimeric antigen receptor (CAR) T lymphocyte therapy. However …

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …

Natural killer (NK) cell therapies have emerged as a potential therapeutic approach to
various cancers. Their efficacy, however, is limited by their low persistence and anergy …

Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened
new avenues towards the development of novel assets to achieve durable immune control …

Bi-, tri-and multispecific antibodies have enabled the development of targeted cancer
immunotherapies redirecting immune effector cells to eliminate malignantly transformed …

Natural killer (NK) cells are lymphocytes with a key role in the defense against viral
infections and tumor cells. Although NK cells are classified as innate lymphoid cells (ILCs) …

Targeted protein degradation (TPD) has emerged in the past decade as a major new drug
modality to remove intracellular proteins with bispecific small molecules that recruit the …